JP2016531138A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016531138A5 JP2016531138A5 JP2016538988A JP2016538988A JP2016531138A5 JP 2016531138 A5 JP2016531138 A5 JP 2016531138A5 JP 2016538988 A JP2016538988 A JP 2016538988A JP 2016538988 A JP2016538988 A JP 2016538988A JP 2016531138 A5 JP2016531138 A5 JP 2016531138A5
- Authority
- JP
- Japan
- Prior art keywords
- spray
- bendamustine
- solid dispersion
- dried solid
- dried
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000007962 solid dispersion Substances 0.000 claims 15
- YTKUWDBFDASYHO-UHFFFAOYSA-N bendamustine Chemical compound ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 YTKUWDBFDASYHO-UHFFFAOYSA-N 0.000 claims 14
- 229960002707 bendamustine Drugs 0.000 claims 14
- 238000001035 drying Methods 0.000 claims 9
- 239000000546 pharmaceutical excipient Substances 0.000 claims 7
- 238000000034 method Methods 0.000 claims 6
- 239000000243 solution Substances 0.000 claims 5
- 239000003125 aqueous solvent Substances 0.000 claims 4
- 238000007664 blowing Methods 0.000 claims 3
- 239000011261 inert gas Substances 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 239000000843 powder Substances 0.000 claims 3
- 238000002360 preparation method Methods 0.000 claims 3
- 239000002177 L01XE27 - Ibrutinib Substances 0.000 claims 2
- 239000007864 aqueous solution Substances 0.000 claims 2
- 150000001720 carbohydrates Chemical class 0.000 claims 2
- 239000007857 degradation product Substances 0.000 claims 2
- 239000002552 dosage form Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 238000009472 formulation Methods 0.000 claims 2
- XYFPWWZEPKGCCK-GOSISDBHSA-N ibrutinib Chemical compound C1=2C(N)=NC=NC=2N([C@H]2CN(CCC2)C(=O)C=C)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 XYFPWWZEPKGCCK-GOSISDBHSA-N 0.000 claims 2
- 229960001507 ibrutinib Drugs 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 239000006199 nebulizer Substances 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 229930195725 Mannitol Natural products 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000012467 final product Substances 0.000 claims 1
- 235000010355 mannitol Nutrition 0.000 claims 1
- 239000000594 mannitol Substances 0.000 claims 1
- 230000000877 morphologic effect Effects 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 230000000704 physical effect Effects 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000007921 spray Substances 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361870609P | 2013-08-27 | 2013-08-27 | |
| US61/870,609 | 2013-08-27 | ||
| PCT/US2014/052341 WO2015031198A2 (en) | 2013-08-27 | 2014-08-22 | Bendamustine pharmaceutical compositions |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016531138A JP2016531138A (ja) | 2016-10-06 |
| JP2016531138A5 true JP2016531138A5 (https=) | 2017-09-28 |
| JP6571657B2 JP6571657B2 (ja) | 2019-09-04 |
Family
ID=52584085
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016538988A Active JP6571657B2 (ja) | 2013-08-27 | 2014-08-22 | ベンダムスチンの薬学的組成物 |
Country Status (11)
| Country | Link |
|---|---|
| US (7) | US9849115B2 (https=) |
| EP (1) | EP3043648B1 (https=) |
| JP (1) | JP6571657B2 (https=) |
| CN (2) | CN109953954A (https=) |
| AU (5) | AU2014311570C1 (https=) |
| CA (1) | CA2922099C (https=) |
| ES (1) | ES2957541T3 (https=) |
| IL (1) | IL244133A0 (https=) |
| MX (2) | MX376522B (https=) |
| WO (1) | WO2015031198A2 (https=) |
| ZA (1) | ZA201601645B (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2957541T3 (es) | 2013-08-27 | 2024-01-22 | Vasilios Voudouris | Composiciones farmacéuticas de bendamustina |
| CA2941632C (en) * | 2014-03-13 | 2023-10-24 | Vasilios VOUDOURIS | Bendamustine solid dispersions and continuous infusion |
| JP6937016B2 (ja) * | 2017-09-06 | 2021-09-22 | 東京理化器械株式会社 | 噴霧乾燥装置 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030203036A1 (en) * | 2000-03-17 | 2003-10-30 | Gordon Marc S. | Systems and processes for spray drying hydrophobic drugs with hydrophilic excipients |
| CA2317106C (en) * | 1997-12-31 | 2004-11-23 | Choongwae Pharma Corporation | Method and composition of an oral preparation of itraconazole |
| SE0000773D0 (sv) | 2000-03-08 | 2000-03-08 | Astrazeneca Ab | New formulation |
| US20030105141A1 (en) | 2001-04-17 | 2003-06-05 | Ping Gao | Finely self-emulsifiable pharmaceutical composition |
| JP4644397B2 (ja) * | 2001-09-05 | 2011-03-02 | 信越化学工業株式会社 | 難溶性薬物を含む医薬用固形製剤の製造方法 |
| AU2002346472A1 (en) | 2001-11-20 | 2003-06-10 | Advanced Inhalation Research, Inc. | Particulate compositions for improving solubility of poorly soluble agents |
| US8436190B2 (en) | 2005-01-14 | 2013-05-07 | Cephalon, Inc. | Bendamustine pharmaceutical compositions |
| CN1887269A (zh) * | 2006-07-25 | 2007-01-03 | 济南帅华医药科技有限公司 | 一种含苯达莫司汀及其增效剂的抗癌缓释注射剂 |
| CN1887261A (zh) * | 2006-07-25 | 2007-01-03 | 济南帅华医药科技有限公司 | 含苯达莫司汀的复方抗癌缓释注射剂 |
| DE102007009242A1 (de) * | 2007-02-22 | 2008-09-18 | Evonik Röhm Gmbh | Pellets mit magensaftresistenter Wirkstoff-Matix |
| US20090130198A1 (en) | 2007-11-21 | 2009-05-21 | Innopharmax Inc. | Pharmaceutical composition with enhanced bioavailability |
| AR072777A1 (es) | 2008-03-26 | 2010-09-22 | Cephalon Inc | Formas solidas de clorhidrato de bendamustina |
| EP2326306A1 (en) | 2008-09-25 | 2011-06-01 | Cephalon, Inc. | Liquid formulations of bendamustine |
| EP2367542B1 (en) | 2008-12-03 | 2014-01-01 | Astellas Deutschland GmbH | Oral dosage forms of bendamustine |
| UA107186C2 (xx) * | 2008-12-03 | 2014-12-10 | Тверді форми дозування бендамустину | |
| WO2010097700A1 (en) * | 2009-02-25 | 2010-09-02 | Supratek Pharma, Inc. | Bendamustine cyclopolysaccharide compositions |
| US20100273730A1 (en) | 2009-04-27 | 2010-10-28 | Innopharmax, Inc. | Self-emulsifying pharmaceutical compositions of hydrophilic drugs and preparation thereof |
| MX2011011109A (es) * | 2009-04-28 | 2011-11-18 | Cephalon Inc | Formulaciones orales de bendamustina. |
| PL3158991T3 (pl) | 2010-01-28 | 2021-09-27 | Eagle Pharmaceuticals, Inc. | Preparaty bendamustyny |
| WO2011103150A2 (en) | 2010-02-18 | 2011-08-25 | Cephalon, Inc. | Lyophilized preparations of bendamustine |
| JO3659B1 (ar) * | 2010-06-02 | 2020-08-27 | Astellas Deutschland Gmbh | أشكال جرعات بينداموستين عن طريق الفم وإستخداماته العلاجية |
| WO2012103226A2 (en) | 2011-01-25 | 2012-08-02 | Dr. Reddy's Laboratories Ltd. | Bendamustine formulations |
| WO2013102920A1 (en) | 2011-11-18 | 2013-07-11 | Astron Research Limited | Stable lyophilized formulation of bendamustine |
| WO2013117969A1 (en) | 2012-02-06 | 2013-08-15 | Fresenius Kabi Oncology Ltd. | Process for preparing stable pharmaceutical compositions of compounds susceptible to hydrolysis |
| EP2814487A4 (en) * | 2012-02-14 | 2015-07-15 | Eagle Pharmaceuticals Inc | FORMULAS FROM BENDAMUSTIN |
| CA2867295C (en) | 2012-03-20 | 2020-08-11 | Eagle Pharmaceuticals, Inc. | Formulations of bendamustine |
| EP2641592A1 (en) | 2012-03-23 | 2013-09-25 | Salmon Pharma GmbH | Pharmaceutical formulation comprising bendamustine |
| WO2014004707A1 (en) | 2012-06-29 | 2014-01-03 | Principia Biopharma Inc. | Formulations comprising ibrutinib |
| ES2957541T3 (es) | 2013-08-27 | 2024-01-22 | Vasilios Voudouris | Composiciones farmacéuticas de bendamustina |
| CA2941632C (en) | 2014-03-13 | 2023-10-24 | Vasilios VOUDOURIS | Bendamustine solid dispersions and continuous infusion |
-
2014
- 2014-08-22 ES ES14840972T patent/ES2957541T3/es active Active
- 2014-08-22 US US14/466,765 patent/US9849115B2/en active Active
- 2014-08-22 CN CN201910051265.7A patent/CN109953954A/zh active Pending
- 2014-08-22 JP JP2016538988A patent/JP6571657B2/ja active Active
- 2014-08-22 CA CA2922099A patent/CA2922099C/en active Active
- 2014-08-22 CN CN201480045199.8A patent/CN105491886B/zh active Active
- 2014-08-22 MX MX2016002502A patent/MX376522B/es active IP Right Grant
- 2014-08-22 EP EP14840972.5A patent/EP3043648B1/en active Active
- 2014-08-22 AU AU2014311570A patent/AU2014311570C1/en active Active
- 2014-08-22 WO PCT/US2014/052341 patent/WO2015031198A2/en not_active Ceased
- 2014-10-20 US US14/519,079 patent/US9061011B1/en active Active
-
2016
- 2016-02-15 IL IL244133A patent/IL244133A0/en unknown
- 2016-02-25 MX MX2020006075A patent/MX2020006075A/es unknown
- 2016-03-09 ZA ZA2016/01645A patent/ZA201601645B/en unknown
-
2017
- 2017-11-16 US US15/815,578 patent/US10786486B2/en active Active
-
2018
- 2018-07-19 AU AU2018206777A patent/AU2018206777A1/en not_active Abandoned
-
2020
- 2020-08-21 US US16/999,908 patent/US20210008036A1/en not_active Abandoned
- 2020-12-08 AU AU2020286183A patent/AU2020286183A1/en not_active Abandoned
- 2020-12-10 AU AU2020286280A patent/AU2020286280A1/en not_active Abandoned
-
2021
- 2021-11-22 US US17/532,874 patent/US11701344B2/en active Active
-
2022
- 2022-11-02 AU AU2022263496A patent/AU2022263496A1/en not_active Abandoned
-
2023
- 2023-05-23 US US18/200,980 patent/US20230310381A1/en not_active Abandoned
-
2024
- 2024-05-16 US US18/665,804 patent/US20240299363A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Chang et al. | Production of highly stable spray dried phage formulations for treatment of Pseudomonas aeruginosa lung infection | |
| JP2009530415A5 (https=) | ||
| JP2015527395A5 (https=) | ||
| NZ707328A (en) | Virus-containing formulation and use thereof | |
| IL298998B1 (en) | Pharmaceutical formulations of a hif hydroxylase inhibitor | |
| AR093012A1 (es) | Composiciones farmaceuticas en polvo, activas, con enmascaramiento del sabor y procesos para su fabricacion | |
| JP2015515968A5 (https=) | ||
| PT2647648T (pt) | Forma de dosagem sólida que contém uma hidroxialquil celulose de baixa viscosidade | |
| JP2016531138A5 (https=) | ||
| MX2017004476A (es) | Composicion que comprende al menos un polvo seco obtenido por secado por atomizacion para aumentar la estabilidad de la formulacion. | |
| JP2017523149A5 (https=) | ||
| JP2007525534A (ja) | 少なくとも部分的に非晶質の状態である敏感な活性物質の粉末組成物 | |
| CN104587472A (zh) | 一种含纳米SiO2的包衣剂及其制备方法 | |
| ES2372983T3 (es) | Proceso para preparar formulaciones secadas por aspersión de tmc125. | |
| JP2010536837A5 (https=) | ||
| CN105106152A (zh) | 一种盐酸决奈达隆组合物 | |
| CN102178677B (zh) | 硝苯地平双层渗透泵药物组合物及其制备工艺 | |
| JP2017048174A (ja) | 化学的に安定な原薬含有被覆粒子を含む口腔内崩壊錠剤 | |
| CN104800184A (zh) | 琥珀酸呋罗曲坦缓释剂片 | |
| CN102772392B (zh) | 一种阿比多尔缓控释胶囊及其制备方法 | |
| CN103637984A (zh) | 一种黄芩苷纳米结晶及其制备方法 | |
| CN100522167C (zh) | 注射用帕洛诺司琼及其药物上可接受的盐的粉针制剂及其制备方法 | |
| WO2020111089A1 (ja) | 医薬組成物 | |
| CN103169691B (zh) | 一种决奈达隆或其盐的粉末及由其制备的药物组合物 | |
| CN102641240B (zh) | 一种苦柯胺b盐注射剂及其制备方法 |